There is a shift in the industry towards biopharmaceuticals, but there is still great demand for synthetic APIs. We catch up with Richard Hercek, Head of API Engineering and IPC, and Boris Petrusek, EU Project Manager, at Saneca Pharma to discuss the latest trends in small-molecule API manufacture.
False
False
Recommended
False
Related Content
The Mindset for Success in Biopharma's New Multipolar World
August 18, 2026
10 min read
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
Musings from The Power List: Ali Pashazadeh
August 7, 2026
7 min read
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
The Confidentiality Barrier to AI-Enabled Drug Development
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
Why Drug Development Still Lacks Integration
July 21, 2026
4 min read
John McDermott reflects on why early drug development remains fragmented – and how integrated approaches may shorten timelines
